Mink Therapeutics, Inc. SEC Filings

Ulf Wiinberg, a director of MiNK Therapeutics, Inc. (INKT), reported a grant and his current holdings. On 09/02/2025 Mr. Wiinberg was granted 1,011 restricted stock units (RSUs) received in lieu of cash board and committee retainers; the RSUs vest one month from the grant date and are valued at $13.86 per share on the filing. Following the grant he beneficially owns 18,971 shares directly and 27,830 shares indirectly held in an irrevocable trust for his family.

MiNK Therapeutics director Robert Peter Kadlec was granted 975 restricted stock units (RSUs) as board and committee compensation on 09/02/2025. The RSUs, received in lieu of cash retainers, represent a contingent right to one share of common stock per RSU and will vest one month from the grant date. Following the award, the reporting person beneficially owns 17,908 shares. The transaction is reported on Form 4 for ticker INKT and was signed by an attorney-in-fact on 09/03/2025.

MiNK Therapeutics director Barbara Ryan received 1,281 restricted stock units (RSUs) as board and committee compensation on 09/02/2025. Each RSU converts to one share of common stock; the reported RSUs were granted in lieu of cash retainers and will vest one month from the grant date. Following the grant, Ms. Ryan beneficially owns 20,805 shares of common stock. The transaction price recorded for the RSUs is $13.86 per share (used for reporting purposes).

Brian Corvese, a director of MiNK Therapeutics, Inc. (INKT), was granted 1,290 restricted stock units (RSUs) on 09/02/2025 as board and committee compensation in lieu of cash. Each RSU represents a contingent right to receive one share of common stock and the grant price shown on the form is $13.86 per share. After the grant, the reporting person beneficially owns 48,441 shares. The RSUs are scheduled to vest one month from the grant date. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

MiNK Therapeutics director Peter Behner received 1,173 restricted stock units (RSUs) on 09/02/2025, granted in lieu of cash board and committee retainers. Each RSU represents a contingent right to one share of common stock and will vest one month from the grant date.

After the grant, Mr. Behner beneficially owns 18,649 shares of MiNK common stock on a direct basis. The reported per-share value associated with the grant is $13.86. The Form 4 was submitted to disclose this change in beneficial ownership.

MiNK Therapeutics (INKT) filed a Form 144 proposing the sale of 786,750 shares of common stock, with an aggregate market value of $12,572,265, to be sold approximately on 08/29/2025 on the INKT exchange. The filing states these shares were originally issued on 07/05/2017 in an original issuance from the issuer when it was a wholly owned subsidiary of Agenus Inc.; the shares were acquired in exchange for Agenus Inc.'s initial capital contribution. The filer reports no securities sold in the past three months and provides the standard representation that no undisclosed material adverse information is known.

MiNK Therapeutics (INKT) reported operational and financing updates in its Form 10-Q. The company completed an Option Exchange that re-priced 647,915 options to an exercise price of $7.43 with a 10-year term and unchanged vesting, producing approximately $0.6 million of incremental share-based compensation expense ($0.4 million recognized immediately and $0.2 million over the remaining vesting period). Agenus-related intercompany activities are disclosed, including a $14.5 million note receivable as of June 30, 2025 that Agenus agreed not to require repayment for the foreseeable future; interest accrues and may convert at Agenus’ election into equity at 80% of a qualified financing price. The company completed a 1-for-10 reverse stock split effective January 28, 2025. Nasdaq compliance for Minimum Value of Listed Securities was restored after MVLS exceeded $35.0 million for the required consecutive period. Clinical highlights include a durable complete remission in a refractory metastatic testicular cancer patient and a durable partial response in an advanced gastric cancer patient following agenT-797 plus checkpoint blockade.